BioNexus Gene Lab Corp. Increase (Decrease) in Other Current Assets
BioNexus Gene Lab Corp. (BGLC) reported Increase (Decrease) in Other Current Assets of $9.76 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2020-03-31
- BioNexus Gene Lab Corp. increase (decrease) in other current assets for the quarter ending 2019-12-31 was $13.64K.
- BioNexus Gene Lab Corp. increase (decrease) in other current assets for the quarter ending 2019-09-30 was -$2.24K.
- BioNexus Gene Lab Corp. increase (decrease) in other current assets for the quarter ending 2019-06-30 was $2.33K, a 804.26% increase year-over-year.
- BioNexus Gene Lab Corp. increase (decrease) in other current assets for the quarter ending 2019-03-31 was -$3.97K, a 103.48% decline year-over-year.
- BioNexus Gene Lab Corp. increase (decrease) in other current assets for fiscal 2019 was $9.76K, a 90.77% decline from fiscal 2018.
- BioNexus Gene Lab Corp. increase (decrease) in other current assets for fiscal 2018 was $105.67K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2019-12-31 | $13.64K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | $11.39K derived: sum of 2 quarters · filed 2020-03-31 | $13.73K derived: sum of 3 quarters · filed 2020-03-31 | $9.76K 10-K · filed 2020-03-31 |
| 2019-09-30 | -$2.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $91.00 derived: sum of 2 quarters · filed 2019-11-14 | -$3.88K 10-Q · filed 2019-11-14 | -$12.05K derived: sum of 4 quarters · filed 2020-03-31 |
| 2019-06-30 | $2.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$1.64K 10-Q · filed 2019-08-09 | -$9.81K derived: sum of 3 quarters · filed 2020-03-31 | -$10.37K derived: sum of 4 quarters · filed 2020-03-31 |
| 2019-03-31 | -$3.97K 10-Q · filed 2019-05-15 | -$12.14K derived: sum of 2 quarters · filed 2020-03-31 | -$12.70K derived: sum of 3 quarters · filed 2020-03-31 | -$12.44K derived: sum of 4 quarters · filed 2020-03-31 |
| 2018-12-31 | -$8.17K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | -$8.73K derived: sum of 2 quarters · filed 2020-03-31 | -$8.47K derived: sum of 3 quarters · filed 2020-03-31 | $105.67K 10-K · filed 2020-03-31 |
| 2018-09-30 | -$559.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$301.00 derived: sum of 2 quarters · filed 2019-11-14 | $113.84K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $258.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $114.40K 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $114.14K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |